A Superlong‐acting Growth Hormone‐polypeptide Fusion for Growth Hormone Deficiency Treatment

Abstract

Recombinant human growth hormone (rhGH) is clinically used to treat growth hormone deficiency. However, daily administration of rhGH is required due to its poor stability and short blood circulation, which causes pains and burdens as well as inconvenience to patients. In this study, a method for genetically fusing rhGH to a thermosensitive polymer of elastin‐like polypeptide (ELP) was reported, using which the rhGH‐ELP thermosensitive fusion protein could be purified by the thermosensitivity of ELP instead of chromatography. The ELP fusion not only drastically improves the stability of rhGH, but also enables the in situ formation of a sustained‐release depot of rhGH‐ELP upon subcutaneous injection, which exhibits gentle release with a platform‐to‐trough fluctuation in blood and a very long circulatory half‐life of 594.6 h. In contrast, rhGH exhibits a peak‐to‐trough fluctuation in blood with a very short circulatory half‐life of 0.7 h. As a result, a single subcutaneous injection of rhGH‐ELP can consecutively promote the linear growth of rats and the development of major tissues and organs over three weeks without obvious side effects, whereas rhGH is required to be injected daily to achieve similar therapeutic results.

This article is protected by copyright. All rights reserved